Which Healthcare Policy Scenarios Remain Possible
With the U.S. election results still uncertain, all the possible scenarios for healthcare policy changes remain on the table.
As of the morning of Nov. 4, control of the major U.S. federal electable bodies still remains uncertain. For now, most news outlets project that the U.S. House of Representatives will remain in the Democratic party's control. However, control of the White House and Senate still remain up in the air, as several states continue to process votes and appear too close to call. We reiterate our undervalued call on the managed care sector and see significant margins of safety built into most of those players' stocks even in our valuation downside policy scenarios, which are possible only in a Democratic sweep scenario.
However, investors should know that we would be unlikely to change our moat ratings or valuations even in a Democratic sweep scenario until legislative plans are more certain. The U.S. still remains in increasing access mode, and current initiatives to expand the insured population create a spectrum of risks and opportunities, with the public option representing the major wildcard. Based on our pricing estimates for the public option, though, we see the potential for major changes on the individual exchanges but only minor changes in the important employer-based market even at the low end of our estimated pricing range. The role of private insurers in the public option could also be a point of compromise in the legislative process since plans from private insurers, like Medicare Advantage, could play a role.
Split control of the U.S. government's federal electable bodies also remains possible, and policy changes that meaningfully change our moat or valuations in the healthcare industry appear unlikely in this scenario. Split control of the U.S. federal electable bodies would likely result in a business as usual regulatory environment for the healthcare industry. However, we think executive orders could create mildly positive effects on the number of insured Americans with a Democrat in the White House and mildly negative effects with Republican control.
|Morningstar Premium Members gain exclusive access to our full analyst reports, including fair value estimates, bull and bear breakdowns, and risk analyses. Not a Premium Member? Get this and other reports immediately when you try Morningstar Premium free for 14 days.|
Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.
We’d like to share more about how we work and what drives our day-to-day business.
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.
How we use your information depends on the product and service that you use and your relationship with us. We may use it to:
To learn more about how we handle and protect your data, visit our privacy center.
Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.
To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.
Read our editorial policy to learn more about our process.